Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $18.95 USD
Change Today -0.37 / -1.92%
Volume 85.2K
TTOO On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

t2 biosystems inc (TTOO) Snapshot

Open
$19.17
Previous Close
$19.32
Day High
$19.32
Day Low
$18.31
52 Week High
08/21/14 - $24.50
52 Week Low
08/6/14 - $11.00
Market Cap
381.4M
Average Volume 10 Days
84.0K
EPS TTM
$-4.15
Shares Outstanding
20.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for T2 BIOSYSTEMS INC (TTOO)

t2 biosystems inc (TTOO) Related Bloomberg News

View More Bloomberg News

t2 biosystems inc (TTOO) Related Businessweek News

No Related Businessweek News Found

t2 biosystems inc (TTOO) Details

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. Its T2 Magnetic Resonance platform enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications; T2Candida panel for identifying pathogens associated with sepsis; and T2MR Platform, a magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. It is also developing T2Stat, an integrated instrument that provides hemostasis measurements; T2HemoStat panel, which includes a set of hemostasis measurements, including platelet function, clotting time, and clot degradation; and T2Bacteria, a multiplex diagnostic panel that detects the bacterial pathogens associated with sepsis. The company has strategic agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease, a tick-borne illness. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

110 Employees
Last Reported Date: 03/4/15
Founded in 2006

t2 biosystems inc (TTOO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $350.0K
Chief Financial Officer and Chief Accounting ...
Total Annual Compensation: $171.9K
Chief Operating Officer
Total Annual Compensation: $89.8K
Compensation as of Fiscal Year 2013.

t2 biosystems inc (TTOO) Key Developments

T2 Biosystems, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 10:00 AM

T2 Biosystems, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 10:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: John P. McDonough, Chief Executive Officer, President and Director.

T2 Biosystems, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

T2 Biosystems, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $8,838,000 against $5,639,000 a year ago. Net loss was $9,076,000 against $6,374,000 a year ago. Net loss applicable to common stockholders was $9,076,000 or $0.45 per basic and diluted share against $8,284 million or $5.89 per diluted share a year ago. For the year, the company reported loss from operations of $30,681,000 against $19,692,000 a year ago. Net loss was $31,390,000 against $20,610,000 a year ago. Net loss applicable to common stockholders was $35,960,000 or $4.15 per diluted share against $27,518,000 or $19.72 per diluted share a year ago.

T2 Biosystems, Inc. to Report Q4, 2014 Results on Feb 17, 2015

T2 Biosystems, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Feb 17, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TTOO:US $18.95 USD -0.37

TTOO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TTOO.
View Industry Companies
 

Industry Analysis

TTOO

Industry Average

Valuation TTOO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,191.5x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,408.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact T2 BIOSYSTEMS INC, please visit www.t2biosystems.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.